44.8亿元买自家CEO的资产:中国生物制药的“折价”生意经

华夏时报网
Yesterday

日前,中国生物制药(01177.HK)公告,拟以44.8亿元现金,向执行董事兼主要股东谢承润收购雍华创投全部股权,从而间接取得核心子公司正大天晴5%股权,持股比例由60%提升至65%。  公告从多个维度阐述了本次交易的价值:以正大天晴LTM经调整归母净利润测算,可增厚集团经调整归母净利润约3.5亿元(约7.4%);收购估值较同业存在折价;提升全体股东回报等。  需要说明的是,本次交易卖方谢承润为...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10